Please login to the form below

Not currently logged in
Email:
Password:

NICE recommends aripiprazole

NICE's FAD recommends the use of Bristol-Myers Squibb's atypical anti-psychotic drug Abilify (aripiprazole) as an option for the treatment of adolescent schizophrenia

The National Institute for Health and Clinical Excellence's (NICE) Final Appraisal Determination (FAD) has recommended the use of Abilify (aripiprazole) as an option for the treatment of schizophrenia in people aged 15 to 17 years who are intolerant of risperidone, or for whom risperidone is contraindicated, or whose schizophrenia has not been adequately controlled with risperidone.

Aripiprazole received its first EU approval in 2004. In the UK it is the only commonly-used atypical anti-psychotic licensed for the treatment of adolescent schizophrenia and the first to be appraised by NICE.

The announcement of NICE's forthcoming guidance, which will offer patients in the UK access to a cost-effective treatment for their condition, has been welcomed by patient groups.

According to Marjorie Wallace, CBE, chief executive of mental health charity, SANE: "Everyone's biochemistry differs and the more we can find a choice of medications to target individual needs, with side-effects that can be tolerated, the more we can help people to manage their condition."

"This is particularly important in teenagers: schizophrenia often strikes at this time and it is vital to find effective treatment and prevent relapse, With better medications and therapies, the lives of young people with schizophrenia can be greatly improved," Wallace said.

1st December 2010

From: Healthcare

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....
Cell and gene therapy
Tackling the manufacturing cost and complexity challenges...

Infographics